AVALO THERAPEUTICS, INC. (AVTX) Current Ratio
- Current ratio · latest quarter: Value 19.31×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 19.31× | Current assets / current liabilities. $407.93M ÷ $21.13M ≈ 19.31× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 407.93M USD | Assets, Current |
| Current obligations | 21.13M USD | Liabilities, Current |
| Cash and equivalents | 85.38M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 3.35M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $407.93M | $21.13M | $85.38M | (m) | (m) | (m) | $3.35M | (m) | 19.31× |
| 2026-03-31 | $88.83M | $11.60M | $24.99M | (m) | (m) | (m) | $356.00K | (m) | 7.66× |
| 2025-12-31 | $105.29M | $12.94M | $15.86M | (m) | (m) | (m) | $137.00K | (m) | 8.14× |
| 2025-09-30 | $113.85M | $7.97M | $26.96M | (m) | (m) | (m) | $474.00K | (m) | 14.28× |
| 2025-06-30 | $115.19M | $9.26M | $42.29M | (m) | (m) | (m) | $2.37M | (m) | 12.44× |
| 2025-03-31 | $126.94M | $5.62M | $125.05M | (m) | (m) | (m) | $681.00K | (m) | 22.61× |
| 2024-12-31 | $138.89M | $6.96M | $134.55M | (m) | (m) | (m) | $283.00K | (m) | 19.96× |
| 2024-09-30 | $86.15M | $60.67M | $81.86M | (m) | (m) | (m) | $1.81M | (m) | 1.42× |
| 2024-06-30 | $95.89M | $96.40M | $93.43M | (m) | (m) | (m) | $654.00K | (m) | 0.99× |
| 2024-03-31 | $111.21M | $215.70M | $110.18M | (m) | (m) | (m) | $916.00K | (m) | 0.52× |
| 2023-12-31 | $8.39M | $4.62M | $7.42M | (m) | (m) | (m) | $446.00K | (m) | 1.82× |
| 2023-09-30 | $12.66M | $6.00M | $10.18M | (m) | (m) | $0.00 | $789.00K | (m) | 2.11× |
| 2023-06-30 | $7.52M | $22.45M | $6.31M | (m) | $38.00K | $18.00K | $751.00K | (m) | 0.33× |
| 2023-03-31 | $19.25M | $23.25M | $16.69M | (m) | (m) | $19.00K | $5.57M | (m) | 0.83× |
| 2022-12-31 | $16.42M | $22.11M | $13.17M | (m) | (m) | $20.00K | $2.88M | (m) | 0.74× |
| 2022-09-30 | $19.45M | $18.15M | $16.94M | (m) | (m) | $22.00K | $1.45M | (m) | 1.07× |
| 2022-06-30 | $15.02M | $15.39M | $11.25M | (m) | (m) | $23.00K | $2.16M | (m) | 0.98× |
| 2022-03-31 | $43.66M | $17.89M | $38.47M | (m) | (m) | $25.00K | $3.76M | (m) | 2.44× |
| 2021-12-31 | $61.84M | $19.89M | $54.59M | (m) | (m) | $38.00K | $3.37M | (m) | 3.11× |
| 2021-09-30 | $77.01M | $19.04M | $71.51M | (m) | (m) | $16.00K | $3.57M | (m) | 4.04× |
| 2021-06-30 | $47.36M | $21.67M | $40.44M | (m) | (m) | $20.00K | $3.96M | (m) | 2.19× |
| 2021-03-31 | $46.10M | $26.36M | $38.29M | (m) | (m) | $0.00 | $11.91M | (m) | 1.75× |
| 2020-12-31 | $26.00M | $15.22M | $18.92M | (m) | (m) | $3.00K | $2.57M | (m) | 1.71× |
| 2020-09-30 | $41.03M | $16.57M | $33.39M | (m) | (m) | $9.06K | $1.93M | (m) | 2.48× |
| 2020-06-30 | $50.24M | $14.60M | $45.39M | (m) | (m) | $12.20K | $2.56M | (m) | 3.44× |
| 2020-03-31 | $25.49M | $15.33M | $5.66M | (m) | (m) | $16.28K | $2.73M | (m) | 1.66× |
| 2019-12-31 | $17.72M | $12.16M | $3.61M | (m) | (m) | $21.33K | $2.08M | (m) | 1.46× |
| 2019-09-30 | $12.59M | $17.26M | $5.25M | (m) | (m) | $402.27K | $826.47K | $1.05M | 0.73× |
| 2019-06-30 | $13.90M | $18.77M | $9.39M | (m) | (m) | $617.61K | $1.45M | $1.05M | 0.74× |
| 2019-03-31 | $26.74M | $28.13M | $16.12M | (m) | (m) | $1.05M | $1.25M | $1.05M | 0.95× |
| 2018-12-31 | $21.93M | $26.22M | $10.65M | (m) | (m) | $317.92K | $1.45M | (m) | 0.84× |
| 2018-09-30 | $18.47M | $24.91M | $6.84M | (m) | (m) | $1.06M | $1.54M | $1.05M | 0.74× |
| 2018-06-30 | $11.84M | $19.05M | $2.18M | (m) | (m) | $1.54M | $2.94M | $1.05M | 0.62× |
| 2018-03-31 | $13.39M | $14.79M | $2.52M | (m) | (m) | $3.44M | $3.17M | $787.50K | 0.91× |
| 2017-12-31 | $10.67M | $11.09M | $2.47M | (m) | (m) | $382.15K | $1.30M | $0.00 | 0.96× |
| 2017-09-30 | $28.11M | $4.83M | $23.96M | (m) | (m) | (m) | $312.51K | $0.00 | 5.82× |
| 2017-06-30 | $5.95M | $1.66M | $5.46M | (m) | (m) | (m) | $327.30K | $607.60K | 3.58× |
| 2017-03-31 | $3.46M | $2.74M | $3.00M | (m) | (m) | (m) | $595.88K | $1.49M | 1.26× |
| 2016-12-31 | $5.66M | $4.31M | $5.13M | (m) | (m) | $0.00 | $1.01M | $2.35M | 1.31× |
| 2016-09-30 | $9.49M | $7.50M | $8.82M | (m) | (m) | (m) | $809.15K | $3.19M | 1.27× |
| 2016-06-30 | $13.13M | $6.59M | $11.88M | (m) | (m) | (m) | $756.46K | $3.39M | 1.99× |
| 2016-03-31 | $16.89M | $6.17M | $16.60M | (m) | (m) | (m) | $591.03K | $3.30M | 2.74× |
| 2015-12-31 | $21.62M | $5.85M | $21.16M | (m) | (m) | (m) | $678.11K | $3.21M | 3.70× |
| 2015-09-30 | $3.41M | $6.65M | $3.31M | (m) | (m) | (m) | $1.95M | $3.13M | 0.51× |
| 2014-12-31 | $12.16M | $4.99M | $11.74M | (m) | (m) | (m) | $931.14K | $1.91M | 2.44× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |